Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Biotechnology

Editor-in-Chief

ISSN (Print): 1389-2010
ISSN (Online): 1873-4316

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Perspective

Liquid Biopsy and Non-small-cell Lung Cancer: Expecting More Fluid Management of Patients

Author(s): Sara Fancelli, Giandomenico Roviello*, Francesca Castiglione, Enrico Caliman, Mazzoni Francesca, Paglialunga Luca, Serena Pillozzi and Lorenzo Antonuzzo

Volume 24, Issue 3, 2023

Published on: 26 August, 2022

Page: [351 - 354] Pages: 4

DOI: 10.2174/1389201023666220509145943

Next »
[1]
Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J. Clin., 2021, 71(3), 209-249.
[2]
Rosell, R.; Moran, T.; Queralt, C.; Porta, R.; Cardenal, F.; Camps, C.; Majem, M.; Lopez-Vivanco, G.; Isla, D.; Provencio, M.; Insa, A.; Massuti, B.; Gonzalez-Larriba, J.L.; Paz-Ares, L.; Bover, I.; Garcia-Campelo, R.; Moreno, M.A.; Catot, S.; Rolfo, C.; Reguart, N.; Palmero, R.; Sánchez, J.M.; Bastus, R.; Mayo, C.; Bertran-Alamillo, J.; Molina, M.A.; Sanchez, J.J.; Taron, M. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med., 2009, 361(10), 958-967.
[http://dx.doi.org/10.1056/NEJMoa0904554] [PMID: 19692684]
[3]
Kobayashi, Y.; Mitsudomi, T. Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy. Cancer Sci., 2016, 107(9), 1179-1186.
[http://dx.doi.org/10.1111/cas.12996] [PMID: 27323238]
[4]
Lazzari, C.; Gregorc, V.; Karachaliou, N.; Rosell, R.; Santarpia, M. Mechanisms of resistance to osimertinib. J. Thorac. Dis., 2020, 12(5), 2851-2858.
[http://dx.doi.org/10.21037/jtd.2019.08.30] [PMID: 32642198]
[5]
Santarpia, M.; Aguilar, A.; Chaib, I.; Cardona, A.F.; Fancelli, S.; Laguia, F.; Bracht, J.W.P.; Cao, P.; Molina-Vila, M.A.; Karachaliou, N.; Rosell, R. Non-small-cell lung cancer signaling pathways, metabolism, and pd-1/pd-l1 antibodies. Cancers, 2020, 12(6), 12.
[http://dx.doi.org/10.3390/cancers12061475] [PMID: 32516941]
[6]
Wahidi, M.M.; Herth, F.; Yasufuku, K.; Shepherd, R.W.; Yarmus, L.; Chawla, M.; Lamb, C.; Casey, K.R.; Patel, S.; Silvestri, G.A.; Feller-Kopman, D.J. Technical aspects of endobronchial ultrasound-guided transbronchial needle aspiration: CHEST guideline and expert panel report. Chest, 2016, 149(3), 816-835.
[http://dx.doi.org/10.1378/chest.15-1216] [PMID: 26402427]
[7]
NCCN Guideline Version. 7. Non-small cell lung cancers; , 2021. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
[8]
Hofman, P. Liquid biopsy for lung cancer screening: Usefulness of circulating tumor cells and other circulating blood biomarkers. Cancer Cytopathol., 2021, 129(5), 341-346.
[http://dx.doi.org/10.1002/cncy.22367] [PMID: 33007153]
[9]
National cancer institute at the national institutes of health 2020. Available from: https://www.cancer.gov/news-events/cancer-currents-blog/2020/fdafoundation-one-cancer-liquid-biopsy-expanded-approval
[10]
Horn, L.; Whisenant, J.G.; Wakelee, H.; Reckamp, K.L.; Qiao, H.; Leal, T.A.; Du, L.; Hernandez, J.; Huang, V.; Blumenschein, G.R.; Waqar, S.N.; Patel, S.P.; Nieva, J.; Oxnard, G.R.; Sanborn, R.E.; Shaffer, T.; Garg, K.; Holzhausen, A.; Harrow, K.; Liang, C.; Lim, L.P.; Li, M.; Lovly, C.M. Monitoring therapeutic response and resistance: Analysis of circulating tumor DNA in patients with ALK+ Lung Cancer. J. Thorac. Oncol., 2019, 14(11), 1901-1911.
[http://dx.doi.org/10.1016/j.jtho.2019.08.003] [PMID: 31446141]
[11]
Schwartzberg, L.S.; Horinouchi, H.; Chan, D.; Chernilo, S.; Tsai, M.L.; Isla, D.; Escriu, C.; Bennett, J.P.; Clark-Langone, K.; Svedman, C. Liquid biopsy mutation panel for non-small cell lung cancer: Analytical validation and clinical concordance. NPJ Precision Oncol., 2020, 4, 15.
[12]
Zhang, Y.L.; Yuan, J.Q.; Wang, K.F.; Fu, X.H.; Han, X.R.; Threapleton, D.; Yang, Z.Y.; Mao, C.; Tang, J.L. The prevalence of EGFR mutation in patients with non-small cell lung cancer: A systematic review and meta-analysis. Oncotarget, 2016, 7(48), 78985-78993.
[http://dx.doi.org/10.18632/oncotarget.12587] [PMID: 27738317]
[13]
Gray, J.E.; Okamoto, I.; Sriuranpong, V.; Vansteenkiste, J.; Imamura, F.; Lee, J.S.; Pang, Y.K.; Cobo, M.; Kasahara, K.; Cheng, Y. Tissue and plasma EGFR mutation analysis in the flaura trial: Osimertinib versus comparator EGFR tyrosine kinase inhibitor as first-line treatment in patients with EGFR-mutated advanced non–small cell lung cancer. Clin. Cancer Res., 2019, 25, 6644-6652.
[14]
Zhou, C.; Imamura, F.; Cheng, Y.; Okamoto, I.; Cho, B.C.; Lin, M.C.; Majem, M.; Gautschi, O.; Gray, J.E.; Boyer, M.J.; Chmielecki, J.; Hartmaier, R.; Bulusu, K.; Barrett, J.C.; Hodge, R.; Saggese, M.; McKeown, A.; Ramalingam, S.S. Early clearance of plasma EGFR mutations as a predictor of response to osimertinib and comparator EGFR-TKIS in the flaura trial. J. Clin. Oncol., 2019, 37(S15), 9020.
[http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.9020]
[15]
Mack, P.C.; Redman, M.W.; Moon, J.; Goldberg, S.B.; Herbst, R.S.; Melnick, M.A.C.; Walther, Z.; Hirsch, F.R.; Politi, K.A.; Kelly, K.; Gandara, D.R. Residual circulating tumor DNA (CtDNA) after two months of therapy to predict progression-free and overall survival in patients treated on S1403 with Afatinib +/- Cetuximab. J. Clin. Oncol., 2020, 38(S15), 9532.
[http://dx.doi.org/10.1200/JCO.2020.38.15_suppl.9532]
[16]
Du, X.; Yang, B.; An, Q.; Assaraf, Y.G.; Cao, X.; Xia, J. Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors. Cell, 2021, 2(2), 100103.
[http://dx.doi.org/10.1016/j.xinn.2021.100103] [PMID: 34557754]
[17]
Guo, N.; Lou, F.; Ma, Y.; Li, J.; Yang, B.; Chen, W.; Ye, H.; Zhang, J.B.; Zhao, M.Y.; Wu, W.J.; Shi, R.; Jones, L.; Chen, K.S.; Huang, X.F.; Chen, S.Y.; Liu, Y. Circulating tumor DNA detection in lung cancer patients before and after surgery. Sci. Rep., 2016, 6(1), 33519.
[http://dx.doi.org/10.1038/srep33519] [PMID: 27641744]
[18]
Chen, K.; Zhang, J.; Guan, T.; Yang, F.; Lou, F.; Chen, W.; Zhao, M.; Zhang, J.; Chen, S.; Wang, J. Comparison of plasma to tissue DNA mutations in surgical patients with non-small cell lung cancer. J. Thorac. Cardiovasc. Surg., 2017, 154(3), 1123-1131.e2.
[http://dx.doi.org/10.1016/j.jtcvs.2017.04.073] [PMID: 28625771]
[19]
Chaudhuri, A.A.; Chabon, J.J.; Lovejoy, A.F.; Newman, A.M.; Stehr, H.; Azad, T.D.; Khodadoust, M.S.; Esfahani, M.S.; Liu, C.L.; Zhou, L.; Scherer, F.; Kurtz, D.M.; Say, C.; Carter, J.N.; Merriott, D.J.; Dudley, J.C.; Binkley, M.S.; Modlin, L.; Padda, S.K.; Gensheimer, M.F.; West, R.B.; Shrager, J.B.; Neal, J.W.; Wakelee, H.A.; Loo, B.W., Jr; Alizadeh, A.A.; Diehn, M. Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discov., 2017, 7(12), 1394-1403.
[http://dx.doi.org/10.1158/2159-8290.CD-17-0716] [PMID: 28899864]
[20]
Aggarwal, C.; Thompson, J.C.; Black, T.A.; Katz, S.I.; Fan, R.; Yee, S.S.; Chien, A.L.; Evans, T.L.; Bauml, J.M.; Alley, E.W.; Ciunci, C.A.; Berman, A.T.; Cohen, R.B.; Lieberman, D.B.; Majmundar, K.S.; Savitch, S.L.; Morrissette, J.J.D.; Hwang, W.T.; Elenitoba-Johnson, K.S.J.; Langer, C.J.; Carpenter, E.L. Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer. JAMA Oncol., 2019, 5(2), 173-180.
[http://dx.doi.org/10.1001/jamaoncol.2018.4305] [PMID: 30325992]
[21]
Food and Drugs Administration. FDA approves osimertinib as adjuvant therapy for non-small cell lung cancer with EGFR mutations., 2021. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-osimertinib-adjuvant-therapy-non-small-cell-lung-cancer-egfrmutations [Accessed on 19 Apr, 2022].
[22]
Wu, Y.L.; Tsuboi, M.; He, J.; John, T.; Grohe, C.; Majem, M.; Goldman, J.W.; Laktionov, K.; Kim, S-W.; Kato, T.; Vu, H.V.; Lu, S.; Lee, K.Y.; Akewanlop, C.; Yu, C.J.; de Marinis, F.; Bonanno, L.; Domine, M.; Shepherd, F.A.; Zeng, L.; Hodge, R.; Atasoy, A.; Rukazenkov, Y.; Herbst, R.S. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N. Engl. J. Med., 2020, 383(18), 1711-1723.
[http://dx.doi.org/10.1056/NEJMoa2027071] [PMID: 32955177]
[23]
ASCO daily news. The impact of adjuvant osimertinib in resectable non–small cell lung cancer Available from: https://dailynews.ascopubs.org/do/10.1200/ADN.21.200497/full/ [Accessed on 19 Apr, 2022].
[24]
West, H.J.; Gyawali, B. Why Not Adore ADAURA?-the trial we need vs. the trial we got. JAMA Oncol., 2021, 7(5), 677-678.
[http://dx.doi.org/10.1001/jamaoncol.2020.6752] [PMID: 33538783]
[25]
Diehl, F.; Schmidt, K.; Choti, M.A.; Romans, K.; Goodman, S.; Li, M.; Thornton, K.; Agrawal, N.; Sokoll, L.; Szabo, S.A.; Kinzler, K.W.; Vogelstein, B.; Diaz, L.A. Jr Circulating mutant DNA to assess tumor dynamics. Nat. Med., 2008, 14(9), 985-990.
[http://dx.doi.org/10.1038/nm.1789] [PMID: 18670422]
[26]
Tie, J.; Kinde, I.; Wang, Y.; Wong, H.L.; Roebert, J.; Christie, M.; Tacey, M.; Wong, R.; Singh, M.; Karapetis, C.S.; Desai, J.; Tran, B.; Strausberg, R.L.; Diaz, L.A., Jr; Papadopoulos, N.; Kinzler, K.W.; Vogelstein, B.; Gibbs, P. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann. Oncol., 2015, 26(8), 1715-1722.
[http://dx.doi.org/10.1093/annonc/mdv177] [PMID: 25851626]
[27]
Beaver, J.A.; Jelovac, D.; Balukrishna, S.; Cochran, R.; Croessmann, S.; Zabransky, D.J.; Wong, H.Y.; Toro, P.V.; Cidado, J.; Blair, B.G.; Chu, D.; Burns, T.; Higgins, M.J.; Stearns, V.; Jacobs, L.; Habibi, M.; Lange, J.; Hurley, P.J.; Lauring, J.; VanDenBerg, D.; Kessler, J.; Jeter, S.; Samuels, M.L.; Maar, D.; Cope, L.; Cimino-Mathews, A.; Argani, P.; Wolff, A.C.; Park, B.H. Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin. Cancer Res., 2014, 20(10), 2643-2650.
[http://dx.doi.org/10.1158/1078-0432.CCR-13-2933] [PMID: 24504125]
[28]
Ohara, S.; Suda, K.; Sakai, K.; Nishino, M.; Chiba, M.; Shimoji, M.; Takemoto, T.; Fujino, T.; Koga, T.; Hamada, A.; Soh, J.; Nishio, K.; Mitsudomi, T. Prognostic implications of preoperative versus postoperative circulating tumor DNA in surgically resected lung cancer patients: A pilot study. Transl. Lung Cancer Res., 2020, 9(5), 1915-1923.
[http://dx.doi.org/10.21037/tlcr-20-505] [PMID: 33209612]
[29]
Gale, D.; Heider, K.; Perry, M.; Marsico, G.; Ruiz-Valdepeñas, A.; Rundell, V.; Wulff, J.; Sharma, G.; Howarth, K.; Gilligan, D.; Harden, S.; Rassl, D.M.; Rintoul, R.; Rosenfeld, N. Residual CtDNA after treatment predicts early relapse in patients with early-stage NSCLC. J. Clin. Oncol., 2021, 39(S15), 8517.
[http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.8517]
[30]
Sardarabadi, P.; Kojabad, A.A.; Jafari, D.; Liu, C-H. Liquid biopsy-based biosensors for MRD detection and treatment monitoring in Non-Small Cell Lung Cancer (NSCLC). Biosensors, 2021, 11(10), 11.
[http://dx.doi.org/10.3390/bios11100394] [PMID: 34677350]
[31]
Socinski, M.A.; Jotte, R.M.; Cappuzzo, F.; Orlandi, F.; Stroyakovskiy, D.; Nogami, N.; Rodríguez-Abreu, D.; Moro-Sibilot, D.; Thomas, C.A.; Barlesi, F.; Finley, G.; Kelsch, C.; Lee, A.; Coleman, S.; Deng, Y.; Shen, Y.; Kowanetz, M.; Lopez-Chavez, A.; Sandler, A.; Reck, M. Atezolizumab for first-line treatment of metastatic nonsquamous nsclc. N. Engl. J. Med., 2018, 378(24), 2288-2301.
[http://dx.doi.org/10.1056/NEJMoa1716948] [PMID: 29863955]
[32]
Reck, M.; Mok, T.S.K.; Nishio, M.; Jotte, R.M.; Cappuzzo, F.; Orlandi, F.; Stroyakovskiy, D.; Nogami, N.; Rodríguez-Abreu, D.; Moro-Sibilot, D.; Thomas, C.A.; Barlesi, F.; Finley, G.; Lee, A.; Coleman, S.; Deng, Y.; Kowanetz, M.; Shankar, G.; Lin, W.; Socinski, M.A.; Reck, M.; Mok, T.S.K.; Nishio, M.; Jotte, R.M.; Cappuzzo, F.; Orlandi, F.; Stroyakovskiy, D.; Nogami, N.; Rodríguez-Abreu, D.; Moro-Sibilot, D.; Thomas, C.A.; Barlesi, F.; Finley, G.; Lee, A.; Coleman, S.; Deng, Y.; Kowanetz, M.; Shankar, G.; Lin, W.; Socinski, M.A. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): Key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir. Med., 2019, 7(5), 387-401.
[http://dx.doi.org/10.1016/S2213-2600(19)30084-0] [PMID: 30922878]

Rights & Permissions Print Cite
Article Metrics
28
3
© 2024 Bentham Science Publishers | Privacy Policy